Tanvex BioPharma (TPE:6541) Beneish M-Score: 17.70 (As of Jul. 05, 2026)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma Beneish M-Score?

Tanvex BioPharma TPE:6541 +2.10% 57 Beneish M-Score is 17.70 as of Jul. 05, 2026. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 825 Biotechnology companies, Tanvex BioPharma ranks worse than 95.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 17.7 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Tanvex BioPharma's Beneish M-Score or its related term are showing as below:

TPE:6541' s Beneish M-Score Range Over the Past 10 Years
Min: -2.72   Med: -1.53   Max: 17.7
Current: 17.7

During the past 13 years, the highest Beneish M-Score of Tanvex BioPharma was 17.70. The lowest was -2.72. And the median was -1.53.


Tanvex BioPharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Beneish M-Score Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.68 -1.53 -2.72 -2.42 17.70

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 0.87 2.96 6.49 17.70

TPE:6541 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Tanvex BioPharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Beneish M-Score falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tanvex BioPharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 11.3501+0.528 * -0.2176+0.404 * 5.475+0.892 * 11.5627+0.115 * 1.1648
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1214+4.679 * -0.062141-0.327 * 0.4053
=17.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$123.2 Mil.
Revenue was 178.953 + 125.337 + 46.819 + 49.862 = NT$401.0 Mil.
Gross Profit was -243.71 + -162.314 + -12.653 + -22.031 = NT$-440.7 Mil.
Total Current Assets was NT$1,497.2 Mil.
Total Assets was NT$7,961.1 Mil.
Property, Plant and Equipment(Net PPE) was NT$2,760.9 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$366.7 Mil.
Selling, General, & Admin. Expense(SGA) was NT$430.2 Mil.
Total Current Liabilities was NT$799.7 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,366.8 Mil.
Net Income was -420.537 + -273.497 + -340.379 + -465.744 = NT$-1,500.2 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.0 Mil.
Cash Flow from Operations was -166.265 + -221.461 + -328.905 + -288.81 = NT$-1,005.4 Mil.
Total Receivables was NT$0.9 Mil.
Revenue was 2.81 + 11.503 + 17.008 + 3.357 = NT$34.7 Mil.
Gross Profit was 1.45 + 6.611 + -0.435 + 0.666 = NT$8.3 Mil.
Total Current Assets was NT$675.6 Mil.
Total Assets was NT$2,735.1 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,827.1 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$289.0 Mil.
Selling, General, & Admin. Expense(SGA) was NT$306.5 Mil.
Total Current Liabilities was NT$348.1 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,488.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(123.234 / 400.971) / (0.939 / 34.678)
=0.307339 / 0.027078
=11.3501

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8.292 / 34.678) / (-440.708 / 400.971)
=0.239114 / -1.099102
=-0.2176

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1497.182 + 2760.887) / 7961.134) / (1 - (675.624 + 1827.144) / 2735.137)
=0.465143 / 0.084957
=5.475

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=400.971 / 34.678
=11.5627

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(289.04 / (289.04 + 1827.144)) / (366.732 / (366.732 + 2760.887))
=0.136585 / 0.117256
=1.1648

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(430.185 / 400.971) / (306.517 / 34.678)
=1.072858 / 8.838947
=0.1214

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1366.766 + 799.66) / 7961.134) / ((1488.224 + 348.14) / 2735.137)
=0.272125 / 0.671397
=0.4053

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1500.157 - 0 - -1005.441) / 7961.134
=-0.062141

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tanvex BioPharma has a M-score of 17.70 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 17.70 mean?
Tanvex BioPharma (TPE:6541) has a Beneish M-Score of 17.70 as of Jul. 05, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #787 out of 825 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Tanvex BioPharma's Beneish M-Score too high?
Tanvex BioPharma's current Beneish M-Score is 17.70. Based on the distribution chart, Tanvex BioPharma ranks #787 out of 825 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #787 out of 825 companies for Beneish M-Score. This places Tanvex BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Beneish M-Score is 17.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Beneish M-Score is 17.70. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Beneish M-Score is 17.70 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • Beneish M-Score: 17.70
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value